How to Reconstitute Egrifta (Tesamorelin): Step-by-Step Guide

What Is Tesamorelin and Why Reconstitution Technique Matters

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) containing all 44 amino acids of endogenous GHRH plus a trans-3-hexenoic acid group that extends its half-life [1]. The FDA approved Egrifta in November 2010 specifically to reduce excess visceral abdominal fat in HIV-infected adults with lipodystrophy [2].

Because the active ingredient is a peptide, it is supplied as a lyophilized (freeze-dried) powder. Peptide bonds hydrolyze in aqueous solution, so the manufacturer lyophilizes the drug to maximize shelf life. Reconstitution converts the powder back into an injectable solution. Errors during that step, using the wrong diluent, introducing air bubbles, or shaking the vial, can denature the peptide or create particulate matter that causes injection-site reactions or reduces bioavailability [3].

Why Technique Directly Affects Efficacy

A 2016 stability study published in the Journal of Pharmaceutical Sciences confirmed that GH-releasing peptide aggregation increases sharply with mechanical agitation and temperature excursions above 8 °C [3]. Swirling rather than shaking is not a minor stylistic point. Vigorous shaking produces foam and protein aggregates that may reduce the effective dose reaching subcutaneous tissue.

Regulatory Background on Egrifta Formulations

Two branded formulations exist. The original Egrifta (approved 2010) required a two-vial kit: one vial of lyophilized powder plus one vial of diluent. Egrifta SV (approved 2019) consolidated the product into a single-vial formulation at 2 mg/mL, requiring only the diluent provided in the kit [2]. Off-label compounded tesamorelin vials (typically 2 mg or 5 mg) follow USP <797> compounding standards and are reconstituted with bacteriostatic water for injection rather than the brand diluent.

Supplies You Need Before You Start

Gathering every item before touching the vial prevents mid-procedure contamination. Missing one item means restarting the entire aseptic sequence.

Required Supplies

• Tesamorelin lyophilized vial (refrigerated, inspect expiry)
• Diluent: 2.1 mL sterile water for injection (brand kit) OR bacteriostatic water for injection (USP) for compounded vials
• Two 1 mL insulin syringes (28 to 31 gauge, 5/16-inch needle), one for reconstitution transfer, one for the injection dose
• Alcohol swabs (70% isopropyl alcohol)
• Sterile gauze or cotton pad
• Puncture-resistant sharps container
• Clean, dry, flat surface (a paper towel works; a sterile drape is preferred)

What to Avoid

Do not use normal saline (0.9% NaCl) or bacteriostatic saline. Sodium chloride can cause aggregation in peptide solutions. Do not use tap water or distilled water, which are not sterile and lack the bacteriostatic agent (benzyl alcohol 0.9%) that preserves multi-use vials [4].

Step-by-Step Reconstitution Protocol

The following protocol applies to both the FDA-approved brand kit and compounded tesamorelin vials. Where the two diverge, differences are noted explicitly.

Step 1: Hand Hygiene and Surface Preparation

Wash hands with soap and water for a minimum of 20 seconds, then dry with a clean towel. The CDC recommends this as the single most effective step in preventing injection-associated infections [5]. Place a clean paper towel on a flat surface. Lay out all supplies.

Step 2: Inspect Both Vials

Hold the lyophilized vial up to light. The powder should appear white to off-white and compact. Any yellow discoloration, clumping, or visible foreign material is a reason to discard. Inspect the diluent vial similarly. The solution should be clear and colorless. Discard and contact the pharmacy if you observe any particulate matter [2].

Step 3: Clean the Vial Stoppers

Wipe the rubber stopper of the tesamorelin vial with an alcohol swab. Use a single firm stroke, not a back-and-forth scrub. Allow 15 to 30 seconds for the alcohol to evaporate completely before needle insertion. Repeat for the diluent vial stopper [4].

Step 4: Draw the Diluent

Using the first insulin syringe, pull back the plunger to draw air equal to the volume of diluent you need:

• Brand Egrifta kit: draw 2.1 mL (note: most 1 mL insulin syringes max at 1 mL, so use a 3 mL syringe for this transfer step, or use the supplied reconstitution needle/syringe if included in the kit)
• Compounded 2 mg vial: draw 1.0 mL of bacteriostatic water for a concentration of 2 mg/mL
• Compounded 5 mg vial: draw 2.5 mL of bacteriostatic water for a concentration of 2 mg/mL

Inject the air into the diluent vial (inverted), then draw the diluent slowly without creating bubbles.

Step 5: Inject Diluent Against the Vial Wall

This is the most consequential step. Insert the needle into the tesamorelin vial at a 45-degree angle, directing the needle tip toward the inner glass wall rather than directly onto the powder cake. Release the diluent slowly so it runs down the wall and layers gently over the powder. Pointing the stream directly at the powder cake produces foam and denatures protein [3].

Step 6: Swirl, Do Not Shake

Set the vial down and swirl it gently in a circular motion for 30 to 60 seconds. The powder should dissolve fully into a clear, colorless solution. If the solution remains cloudy or shows floating particulates after 90 seconds of swirling, discard the vial. Do not inject a cloudy solution.

Step 7: Inspect the Reconstituted Solution

Hold the vial to the light at a slight angle. A properly reconstituted tesamorelin solution is clear and colorless, similar in appearance to plain water. Cloudiness, visible particles, or color change (yellow, pink) all indicate degradation or contamination.

Step 8: Draw Your Dose

Using a fresh, capped insulin syringe (28 to 31 gauge), clean the vial stopper again with an alcohol swab and allow it to dry. Invert the vial, insert the needle, and draw your prescribed dose. Remove any air bubbles by gently tapping the syringe and slowly depressing the plunger to expel air only.

The HealthRX dosing-volume framework below translates prescribed dose into syringe units based on reconstituted concentration. A prescribing clinician should confirm these volumes before the patient fills a syringe independently.

| Reconstituted Concentration | Prescribed Dose | Volume to Draw | Units on U-100 Syringe | |---|---|---|---| | 1 mg/mL | 1 mg | 1.0 mL | 100 units | | 2 mg/mL | 1 mg | 0.5 mL | 50 units | | 2 mg/mL | 2 mg | 1.0 mL | 100 units | | 4 mg/mL | 2 mg | 0.5 mL | 50 units |

Step 9: Inject Subcutaneously into the Abdomen

Choose a periumbilical site at least 2 inches from the navel. Pinch 1 to 2 inches of skin between thumb and forefinger. Insert the needle at a 90-degree angle (or 45 degrees if body-fat tissue is thin). Inject slowly and steadily. Release pinched skin, withdraw the needle, and apply gentle pressure with gauze. Do not rub the site, which can disperse the depot and increase bruising [2].

Rotate injection sites daily. A consistent rotation map, top right, top left, bottom right, bottom left, reduces site lipohypertrophy, which is particularly relevant for a drug used long-term in patients with HIV-related adipose changes [6].

Step 10: Disposal

Place the used needle and syringe immediately into a puncture-resistant sharps container. Never recap by hand. FDA regulations under RCRA require proper sharps disposal; many states have mail-back programs [7].

Bacteriostatic Water vs. Sterile Water: Which Diluent Is Correct?

The diluent choice depends on the formulation you are using, and mixing them up is a common, consequential error.

Brand Egrifta Kit

The brand kits include a vial of sterile water for injection (SWFI). SWFI contains no preservative. The manufacturer's prescribing information states the solution must be used immediately after reconstitution and any unused portion discarded [2]. SWFI supports single-dose use only.

Compounded Tesamorelin Vials

Compounding pharmacies operating under USP <797> standards use bacteriostatic water for injection (BWFI), which contains 0.9% benzyl alcohol as a preservative [4]. BWFI extends the beyond-use date of the reconstituted solution to up to 28 days when refrigerated at 2 to 8 °C. The 0.9% benzyl alcohol concentration falls within the safe range for repeated subcutaneous administration in adults; however, benzyl alcohol is contraindicated in neonates due to risk of gasping syndrome and should not be used in patients with known benzyl alcohol hypersensitivity [4].

A 2022 USP <797> update tightened beyond-use date (BUD) requirements for Category 1 and Category 2 compounded sterile preparations. Compounded tesamorelin with BWFI in a refrigerated, sealed vial qualifies as Category 2 under the updated standard, supporting a 28-day BUD at 2 to 8 °C provided the preparation was made under appropriate ISO 5 conditions [8].

Syringe Selection: Gauge, Length, and Volume

Syringe selection is not trivial for subcutaneous peptide injections. Using the wrong gauge causes unnecessary pain; using the wrong length risks intramuscular delivery.

Gauge Recommendations

The Endocrine Society clinical practice guidelines on growth-hormone-related therapies recommend 28 to 31 gauge needles for subcutaneous peptide injections to minimize pain and tissue trauma [9]. A 31-gauge, 5/16-inch (8 mm) needle is the most common choice and is widely available as a standard insulin syringe.

Volume and Syringe Type

A 1 mL U-100 insulin syringe is calibrated in 1-unit (0.01 mL) increments. For a 2 mg/mL concentration and a 2 mg dose, the patient draws to the 100-unit mark, representing 1.0 mL. This single-unit precision matters because dose errors in peptide therapy translate directly to efficacy or safety deviations. Tuberculin (TB) syringes (1 mL, not U-100) are an acceptable alternative and are also graduated to 0.01 mL.

Needle Length by Body Habitus

| Body Type | Recommended Needle Length | |---|---| | Low subcutaneous fat (<10 mm pinch) | 4 mm (5/32 inch) at 90° | | Average (>10 mm pinch) | 6 to 8 mm (1/4 to 5/16 inch) at 90° | | High subcutaneous fat | 8 to 12.7 mm (5/16 to 1/2 inch) at 45° |

Intramuscular delivery of tesamorelin is not recommended and has not been studied in pharmacokinetic trials for this indication [2].

Storage: Before and After Reconstitution

Lyophilized Powder

Store Egrifta powder vials at 2 to 8 °C (36 to 46 °F). Do not freeze. Do not expose to direct light for extended periods. The FDA-approved label states vials may be kept at room temperature (up to 25 °C / 77 °F) for a single day if refrigeration is transiently unavailable, but this is not recommended practice for routine storage [2].

Reconstituted Brand Solution

The brand prescribing information is unambiguous: use immediately and discard any unused portion. Tesamorelin reconstituted in SWFI has no preservative and is vulnerable to microbial contamination within hours at room temperature [2].

Reconstituted Compounded Solution (BWFI)

Refrigerate at 2 to 8 °C. Do not freeze. Keep away from light. Discard after 28 days or on the beyond-use date labeled by the compounding pharmacy, whichever comes first. Before each use, inspect for particulate matter and color changes. A previously clear solution that now appears cloudy must be discarded even if the BUD has not passed [8].

Dosing Reference: Standard and Weight-Based Considerations

The FDA-approved dose for Egrifta is 2 mg once daily subcutaneously [2]. Clinical trials that established this dose used it in HIV-infected adults with excess visceral fat; the key Phase 3 trials (LIPO-010 and LIPO-011, combined N=816) demonstrated that 2 mg/day for 26 weeks significantly reduced visceral adipose tissue area by a mean of 26.6 cm² versus placebo (P<0.001) [10].

Dose adjustment for renal or hepatic impairment has not been formally studied. The prescribing information does not recommend dose modification based on body weight; the 2 mg flat dose was used across a range of body sizes in the key trials [2].

For patients who miss a dose, the label instructs skipping the missed dose entirely and resuming the next scheduled dose. Doubling is not recommended and could transiently raise IGF-1 above the normal range, increasing the risk of fluid retention, arthralgia, or carpal tunnel symptoms [2].

Tesamorelin's effect on visceral fat is not maintained after discontinuation. The LIPO-010 extension study showed that visceral adipose tissue returned toward baseline within 6 months of stopping therapy, underscoring the need for ongoing treatment in appropriate patients [10].

Common Reconstitution Errors and How to Avoid Them

Error 1: Shaking the Vial

Vigorous shaking denatures the peptide through mechanical agitation. The correct action is swirling. This distinction appears in both the brand package insert and USP peptide compounding guidance [2] [8].

Error 2: Injecting Diluent Directly Onto the Powder Cake

Directing the diluent stream at the center of the lyophilized cake creates foam and local heat that degrades the peptide at the surface. Always angle the needle toward the glass wall [3].

Error 3: Using the Wrong Diluent

Bacteriostatic saline (0.9% NaCl with benzyl alcohol) is not interchangeable with bacteriostatic water for injection. Sodium chloride has been shown to accelerate aggregation in certain GH-related peptides [3]. Use sterile water for injection with the brand kit and bacteriostatic water for injection with compounded vials.

Error 4: Skipping Visual Inspection

A 2020 FDA advisory on injectable drug products noted that particulate contamination from improper reconstitution is a leading cause of injection-site adverse events for biological injectables [7]. Visual inspection before every injection takes less than 15 seconds and catches degraded product before it is administered.

Error 5: Storing Reconstituted Brand Solution

Patients sometimes refrigerate leftover reconstituted Egrifta (brand) for the next day. The brand kit uses SWFI with no preservative. This practice risks microbial growth. Only compounded vials reconstituted with BWFI can be stored for multiple uses [2].

Clinical Efficacy Context: Why Patients Use Tesamorelin

Understanding why tesamorelin is prescribed helps clinicians and patients take the reconstitution protocol seriously. HIV-associated lipodystrophy affects an estimated 40 to 50% of HIV-infected patients on antiretroviral therapy and carries metabolic and psychological consequences beyond cosmetic concern [11].

The key LIPO-010 and LIPO-011 Phase 3 trials (combined N=816) showed that tesamorelin 2 mg/day for 26 weeks reduced visceral adipose tissue area by 26.6 cm² compared with a 0.6 cm² increase in the placebo group (P<0.001) [10]. IGF-1 levels rose by a mean of 96.4 ng/mL in the tesamorelin group, remaining within the normal age-adjusted range in most participants [10].

The Endocrine Society's 2020 clinical practice guideline on growth hormone therapy in adults notes that growth-hormone-releasing hormone analogues such as tesamorelin produce more physiological pulsatile GH release compared with exogenous GH administration, which may account for the relatively favorable safety profile observed in the key trials [9].

Safety Considerations Specific to Tesamorelin

Tesamorelin stimulates endogenous GH secretion, which raises IGF-1. Elevated IGF-1 over time may increase fluid retention, joint pain, and, theoretically, insulin resistance. Monitor fasting glucose and IGF-1 at baseline and at 3-month intervals during therapy [2].

Tesamorelin is contraindicated in patients with active malignancy, pregnancy, and hypersensitivity to tesamorelin or any component of the formulation. The drug should not be used in patients with disruption of the hypothalamic-pituitary axis (e.g., following pituitary surgery, head irradiation, or trauma) because the mechanism depends on an intact GH axis [2].

Injection-site reactions occurred in 4.8% of tesamorelin-treated patients in key trials versus 3.0% in placebo [10]. Proper rotation of sites and correct injection technique reduce this incidence substantially.